Clinical Trial Update: Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Novartis' Phase 1 dose-finding trial of TNO155 in adults with advanced solid tumors has been terminated. No efficacy results are provided in this update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Esophageal Squamous Cell Carcinoma
• Gastrointestinal Stromal Tumor
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• TNO155 (TNO155)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC | Phase 1 | Status: TERMINATED